BUSINESS DESCRIPTION (Narrative) (Details)						3 Months Ended	12 Months Ended
	Apr. 14, 2019 USD ($) shares	Jan. 15, 2019 USD ($)	Dec. 20, 2018	Sep. 07, 2018 USD ($) shares	Jun. 29, 2017	Apr. 14, 2019 USD ($) shares	Dec. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($)
Business Acquisition [Line Items]
Stock split and reverse stock split							0.033
Accumulated Net Income (Loss)							$ 15,700,000
Working deficiency							12,000,000
Net cash used in operating activities							(6,754,000)	$ (6,690,000)
Value of shares issued								$ 7,784,000
Proceeds from issuance of common stock							2,008,000
Maximum
Business Acquisition [Line Items]
Stock split and reverse stock split			0.5
Lincoln Park [Member]
Business Acquisition [Line Items]
Value of shares issued				$ 10,000,000
Proceeds from issuance of common stock							$ 1,400,000
Shares sold in offering (in shares) | shares							4,928,859
Lincoln Park [Member] | Maximum
Business Acquisition [Line Items]
Value of shares issued				$ 1,000,000			$ 10,000,000
Shares sold in offering (in shares) | shares				450,000
Subsequent Events | Lincoln Park [Member]
Business Acquisition [Line Items]
Proceeds from issuance of common stock	$ 1,400,000					$ 2,400,000
Shares sold in offering (in shares) | shares	4,928,859					14,971,141
Subsequent Events | Crede
Business Acquisition [Line Items]
Proceeds from issuance of common stock		$ 4,000,000
Transgenomics
Business Acquisition [Line Items]
Merger transaction, effective date					Jun. 29, 2017
Merger transaction, agreement date					Oct. 12, 2016
Merger transaction, name of acquired entity					Precipio Diagnostics, LLC, a privately held Delaware limited liability company
Merger transaction, reverse stock split description					effected a 1-for-30 reverse stock split of its common stock
Stock split and reverse stock split					30
Merger transaction, pre-reverse stock split exchange ratio					10.2502